In Vitro and In Vivo Hepatic Differentiation of Adult Somatic Stem Cells and Extraembryonic Stem Cells for Treating End Stage Liver Diseases.
In Vitro and In Vivo Hepatic Differentiation of Adult Somatic Stem Cells and Extraembryonic Stem Cells for Treating End Stage Liver Diseases.
复制标题
DOI：
10.1155/2015/871972
复制
发表时间：
2015
影响因子：
4.3
通讯作者：
Li L
中科院分区：
文献类型：
--
作者：
Hu C;Li L
肝脏捐献者的短缺是阻止大多数患者接受肝脏移植的主要障碍，并将他们列入捐献肝脏组织的等待名单。然后，原代肝细胞移植和生物人工肝已经成为这些致命疾病的两种替代治疗方法。然而，另一个问题出现了。用于肝再生的功能性肝细胞供应短缺，并且它们在从肝组织分离后在体外立即去分化。替代的基于干细胞的治疗策略，包括肝干细胞（HSC）、胚胎干细胞（ESC）、诱导多能干细胞（iPSC）和间充质干细胞（MSC），更有希望，并且由于细胞的高效力和增殖能力，更多的注意力已经投入到这些方法中。本文就成体干细胞和胚外干细胞的一般特性及其在肝诱导分化治疗终末期肝病方面的研究进展作一综述。干细胞向肝脏的分化为肝脏疾病的细胞治疗和组织工程治疗提供了一个理想的和有前途的来源。
The shortage of liver donors is a major handicap that prevents most patients from receiving liver transplantation and places them on a waiting list for donated liver tissue. Then, primary hepatocyte transplantation and bioartificial livers have emerged as two alternative treatments for these often fatal diseases. However, another problem has emerged. Functional hepatocytes for liver regeneration are in short supply, and they will dedifferentiate immediately in vitro after they are isolated from liver tissue. Alternative stem-cell-based therapeutic strategies, including hepatic stem cells (HSCs), embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), and mesenchymal stem cells (MSCs), are more promising, and more attention has been devoted to these approaches because of the high potency and proliferation ability of the cells. This review will focus on the general characteristics and the progress in hepatic differentiation of adult somatic stem cells and extraembryonic stem cells in vitro and in vivo for the treatment of end stage liver diseases. The hepatic differentiation of stem cells would offer an ideal and promising source for cell therapy and tissue engineering for treating liver diseases.